|
|
|
|
|
03.07.25 - 08:48
|
Republishing of: NextCell announces strategic collaboration with FUJIFILM Biosciences (Cision)
|
|
|
NextCell Pharma AB's ("NextCell" or "the Company") has entered into a strategic collaboration with FUJIFILM Biosciences Inc. to bring together their core competences in mesenchymal stromal cells (MSCs) and raw materials for the life science sector. The aim of the collaboration is to provide researchers and developers in the cell therapy field with an integrated offering – standardised MSC products, optimised culture media, and cryopreservation solutions.
As part of the rebranding of Fujifilm Irvine Scientific to FUJIFILM Biosciences, we are re-publishing the press release originally issued...
|
|
|
|
|
02.07.25 - 07:03
|
Ad-hoc News: BioVersys AG (EQS)
|
|
|
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL CANDIDATE...
|
|
|
|
|
|
|
|
|
|
|
30.06.25 - 04:18
|
Medipal′s Yoda on Business Strategy (Bloomberg)
|
|
|
Toshihide Yoda, Senior Managing Director at Japan's biggest wholesaler of pharmaceuticals, Medipal, discusses the company's investment and growth strategies as it plans to evaluate cash deployment strategies to ensure better returns to shareholders. He speaks with Shery Ahn and Haidi Stroud-Watts on "Bloomberg: The Asia Trade". (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
25.06.25 - 09:09
|
Takeda Announces New Assignments of Directors (Business Wire)
|
|
|
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meeting of Shareholders, held in Osaka today.
Takeda's Board of Directors has 11 members serving as external directors out of a total of 14 members, helping to ensure transparency and objectivity. An external director will continue to chair the Board of Directors. The Audit and Supervisory Committee, the Nomination Committee and the Compensation Committee will be composed solely of external directors including their chairs.
Takeda highly values strong, independent governance and its Board of Directors helps to ensure that all decisions and actions are in the best interests of global stakeholders and aligned with the company's values. This robust corporate governance model has been, and will continue to be, critical to Takeda's success.
Details of the new assignments are as follows:
1. New Assignment of Directo...
|
|
|
24.06.25 - 13:33
|
Neuron23 Announces $96.5 Million Series D Financing and First Patient Dosed in Global Phase 2 NEULARK Clinical Trial of NEU-411 for Early Parkinson′s Disease (Business Wire)
|
|
|
NEULARK trial to evaluate NEU-411, a brain-penetrant, potent and selective LRRK2 inhibitor, in people with LRRK2-driven Parkinson's disease; topline data anticipated in 2027SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the closing of a $96.5 million Series D financing round led by a healthcare investor, with significant support from existing investors Westlake Village BioPartners, SoftBank Vision Fund 2, Redmile Group, Blue Owl, Kleiner Perkins, HBM Healthcare Investments (Cayman) Ltd., and Acorn Bioventures. The Company also announced the first patient has been dosed in the global Phase 2 NEULARK clinical trial of NEU-411, a brain-penetrant, potent and selective inhibitor of LRRK2, in people with early Parkinson's disease (PD).
“The Series D financing represents further endorsement of Neuron23's industry-leading approach, w...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
